Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DYNE-101 multiple ascending dose study in myotonic dystrophy type 1
NL-OMON56459Phase 1Recruiting
- Sponsor
- Dyne Therapeutics
- Start
- Mar 2023
- Modality
- Antibody Conjugates → Antibody-Based Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of zeleciment basivarsen in myotonic dystrophy type 1 (DM1) (6 arms), sponsored by Dyne Therapeutics. Primary endpoint: Treatment-emergent adverse events. Started Mar 2023; status: recruiting.
02
Drugs
zeleciment basivarsen
03
Conditions
myotonic dystrophy type 1 (DM1)
Beyond the preview
Go deeper on NL-OMON56459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56459.